SILO
Income statement / Annual
Last year (2025), SILO Pharma Inc's total revenue was $72.10 K,
a decrease of 0.00% from the previous year.
In 2025, SILO Pharma Inc's net income was -$4.23 M.
See SILO Pharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$72.10 K |
$72.10 K |
$72.10 K |
$72.10 K |
$71.26 K |
$0.00 |
$40.57 K |
$0.00 |
$847.41 K |
-$669.48 K |
| Cost of Revenue |
$886.06 K
|
$5.84 K
|
$5.84 K
|
$5.84 K
|
$5.00 K
|
$0.00
|
$27.39 K
|
$17.55 K
|
$0.00
|
$0.00
|
| Gross Profit |
-$813.96 K
|
$66.26 K
|
$66.26 K
|
$66.26 K
|
$66.26 K
|
$0.00
|
$13.18 K
|
-$17.55 K
|
$847.41 K
|
-$669.48 K
|
| Gross Profit Ratio |
-11.29
|
0.92
|
0.92
|
0.92
|
0.93
|
0
|
0.32
|
0
|
1
|
1
|
| Research and Development Expenses |
$2.16 M
|
$2.37 M
|
$845.09 K
|
$1.29 M
|
$693.91 K
|
$26.25 K
|
$63.47 K
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$2.15 M
|
$2.40 M
|
$3.08 M
|
$2.43 M
|
$2.27 M
|
$0.00
|
$864.18 K
|
$459.83 K
|
$313.37 K
|
$300.99 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.15 M
|
$2.40 M
|
$3.08 M
|
$2.43 M
|
$2.27 M
|
$2.18 M
|
$864.18 K
|
$459.83 K
|
$313.37 K
|
$300.99 K
|
| Other Expenses |
-$841.76 K
|
$0.00
|
$0.00
|
-$20.00 K
|
-$148.50 K
|
$0.00
|
$15.94 K
|
$314.61 K
|
$177.50 K
|
$142.50 K
|
| Operating Expenses |
$3.47 M
|
$4.77 M
|
$3.92 M
|
$3.69 M
|
$2.81 M
|
$2.20 M
|
$943.59 K
|
$459.83 K
|
$490.87 K
|
$443.49 K
|
| Cost And Expenses |
$4.35 M
|
$4.78 M
|
$3.93 M
|
$3.70 M
|
$2.82 M
|
$2.20 M
|
$970.97 K
|
$459.83 K
|
$427.96 K
|
$443.49 K
|
| Interest Income |
$193.91 K
|
$333.17 K
|
$398.53 K
|
$72.64 K
|
$1.21 K
|
$11.54 K
|
$12.20 K
|
$4.22 K
|
$20.48 K
|
$49.84 K
|
| Interest Expense |
$37.30 K
|
$5.08 K
|
$4.87 K
|
$2.20 K
|
$3.04 K
|
$269.27 K
|
$62.93 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$11.44 K
|
$6.19 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$17.55 K
|
$0.00
|
$719.32 K
|
| EBITDA |
-$4.18 M |
-$4.38 M |
-$3.63 M |
-$3.91 M |
$4.19 M |
-$2.40 M |
-$950.37 K |
-$951.91 K |
$356.54 K |
$0.00 |
| EBITDA Ratio |
-57.96
|
-60.77
|
-50.29
|
-54.16
|
58.73
|
0
|
-23.43
|
0
|
0.42
|
0
|
| Operating Income Ratio |
-59.37
|
-65.26
|
-53.47
|
-50.31
|
-38.51
|
0
|
-22.93
|
0
|
-0.56
|
0.59
|
| Total Other Income/Expenses Net |
$52.96 K
|
$312.81 K
|
$224.51 K
|
-$279.73 K
|
$6.93 M
|
-$464.55 K
|
-$82.89 K
|
-$375.22 K
|
$826.92 K
|
-$719.32 K
|
| Income Before Tax |
-$4.23 M
|
-$4.39 M
|
-$3.63 M
|
-$3.91 M
|
$4.18 M
|
-$2.67 M
|
-$1.01 M
|
-$969.46 K
|
$356.54 K
|
-$1.11 M
|
| Income Before Tax Ratio |
-58.63
|
-60.93
|
-50.36
|
-54.19
|
58.68
|
0
|
-24.98
|
0
|
0.42
|
1.66
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$24.88 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$4.23 M
|
-$4.39 M
|
-$3.70 M
|
-$3.91 M
|
$3.90 M
|
-$3.04 M
|
-$1.01 M
|
-$969.46 K
|
$356.54 K
|
-$1.11 M
|
| Net Income Ratio |
-58.63
|
-60.93
|
-51.33
|
-54.21
|
54.78
|
0
|
-24.98
|
0
|
0.42
|
1.66
|
| EPS |
-7.5 |
-17.85 |
-18 |
-25.65 |
19.8 |
-35.25 |
-18.6 |
-14.85 |
7.5 |
-16.65 |
| EPS Diluted |
-7.5 |
-17.85 |
-18 |
-25.65 |
19.5 |
-35.25 |
-18.6 |
-14.85 |
7.5 |
-16.65 |
| Weighted Average Shares Out |
$558.82 K
|
$245.36 K
|
$205.32 K
|
$152.28 K
|
$126.49 K
|
$87.94 K
|
$56.15 K
|
$65.47 K
|
$66.78 K
|
$66.93 K
|
| Weighted Average Shares Out Diluted |
$558.82 K
|
$245.36 K
|
$205.32 K
|
$152.28 K
|
$127.90 K
|
$87.94 K
|
$56.15 K
|
$65.47 K
|
$69.44 K
|
$66.93 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
